Follow Us
HIV Treatment and Medical Care

Zerit (Stavudine, d4T)

The Latest

An Overview of Zerit (Stavudine, d4T) Img

An Overview of Zerit (Stavudine, d4T)

Brand Name: Zerit Other Name: d4T Drug Class: Nucleoside Reverse Transcriptase Inhibitors WARNING:


Stavudine (d4T) Phase-Out Festival in Delhi

On 18 May 2012, more than 80 People Living with HIV with prominent side effects from stavudine (d4T), protested at a "Stavudine Phase-Out Festival" demanding immediate phase out of the ARV from India's National Antiretroviral Treatment (ART) program....


Brand name: Zerit Generic name: stavudine, or d4T Class: Nucleotide reverse transcriptase inhibitor(nucleotide, NtRTI, or nuke) Manufacturer: Bristol-Myers Squibb,, (800) 321-1335 AWP: $493.38 (generic $411.16)/month for 40 mg capsule...

Stavudine (Zerit)

What Is Stavudine? Who Should Take Stavudine? What About Drug Resistance? How Is Stavudine Taken? What Are the Side Effects? How Does Stavudine React With Other Drugs? What Is Stavudine? Stavudine (Zerit) is a drug used as part of antir...

Zerit (Stavudine)

Zerit is supplied in 15 mg, 20 mg, 30 mg and 40 mg capsules, and as an oral solution. A new, extended-release formulation, "Zerit XR," can be taken just once per day. The regular 40-mg capsule (shown) is dark orange and imprinted with "BMS 1967" and ...


Two Studies Shed Light on Development of d4T Resistance

Reverse transcriptase (RT) mutation patterns from ZDV-naive subjects failing d4T-containing regimens (Poster, TuPeA3014) Authored by J.E. Hernandez, A. Scarsella, J. Kaiser, L. Ross, R. Fisher, M. Johnson, N. Graham, M. St Clair Development o...


ddI, d4T and Hydroxyurea Side Effect Warning!

The FDA recently issued a warning that when using ddI (didanosine, Videx), some people may develop pancreatitis (a potentially life-threatening inflammation of the pancreas). An early symptom includes severe abdominal pain, which should be carefully ...


Session 84, Abstract 661: A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count 3

In this study by Fisher, et al., 137 treatment-naïve patients with fewer than 500 T-cells were randomized to receive either d4T+ddI or AZT+ddI to determine tolerability and antiretroviral effect. The poster presented in Chicago showed data on 112 pat...


Antiviral Activity and Acceptance of Two Different Triple Combinations

d4T + Indinavir + 3TC Vs d4T + Indinavir + ddI In this study by a Spanish research group led by N. Villalba, 96 AZT-experienced patients with fewer than 350 CD4 cells/mm3 received standard doses of the nucleoside analog d4T in combination with the p...


Session 50, Abstract 379: Combination Therapy with AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients with Less than 200 CD4/mm3

In this non-randomized study, Dr. Rubio and colleagues looked at the efficacy and tolerance of combination therapy with AZT + 3TC + indinavir as compared to d4T + 3TC + indinavir. They enrolled forty-four pre-treated patients (either AZT and/or ddI a...